Danseo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Danseo

Property Description
Active Ingredients Drospirenone (DRSP), Ethinyl Estradiol (EE)
Form Oral Contraceptive Tablet (Film-coated)
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medication is Danseo? (Identity and Classification)

Danseo is a prescription-only, fixed-dose combination product classified as a Combined Oral Contraceptive (COC). This places it within the broader pharmacological group of Hormonal Contraceptives for Systemic Use. This classification is reserved for oral tablets that contain both a synthetic estrogen and a synthetic progestin. This class of medication is designed to provide systemic hormonal regulation. Danseo is intended for regular administration to females of reproductive potential, and its primary, defining purpose is the effective and reversible prevention of pregnancy, which is the most common use scenario for this class.

The Composition of Danseo: Synthetic Hormones and Unique Action

The core active ingredients in Danseo are two synthetic hormones: Drospirenone (DRSP) and Ethinyl Estradiol (EE). Ethinyl Estradiol serves as the estrogen component, while Drospirenone is a synthetic progestin that is structurally derived as a spironolactone analogue. This specific molecular structure distinguishes the drug from many other older-generation progestin-containing COCs. Drospirenone possesses supplementary properties, including known anti-mineralocorticoid and anti-androgenic activities. This component offers effects on fluid balance and androgen-related factors, a feature clinically recognized for differentiating this formulation.

What is the General Purpose of Danseo?

The primary general purpose of Danseo is highly reliable contraception for females of reproductive potential. The combined hormonal action works fundamentally by suppressing pituitary hormones, leading to the inhibition of ovulation, preventing the development and release of an egg. The unique pharmacological profile afforded by the Drospirenone component provides secondary general benefits by influencing hormone-related physiological factors, which is why this combination is often chosen. The medication is uniformly delivered as an Oral Contraceptive Tablet taken by mouth. The overall effectiveness of this specific combination is a primary characteristic of its clinical application.

Regulatory References

  1. NIH: Mechanism of Action for Combined Oral Contraceptives

What side effects are possible with Danseo?

Possible Side Effects and Safety Information for Danseo

Adverse reactions and safety profiles for prescription medications are rigorously documented in official regulatory sources, such as the prescribing information approved by authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These official documents categorize potential side effects by frequency (e.g., very common, common, rare) and by the body system affected (System-Organ Class).

Official Regulatory Status of Safety Data

Data Element Status in Public Regulatory Documents
Key Adverse Reactions Not explicitly published in a standard regulatory label format for this drug.
Frequency Classification No formal frequency framework (e.g., Very Common, Rare) available.
Serious Adverse Reactions Specific severe events are not publicly documented in official regulatory summaries.
Population-Specific Safety No special considerations for pediatric, geriatric, or other specific populations are currently detailed in public summaries.
Safety Restrictions No formal safety-related contraindications or limitations are publicly documented.

Understanding the Safety Profile

The full safety profile of Danseo, including the complete list of adverse reactions, their documented incidence rates, and specific safety monitoring requirements, is typically outlined in the approved Prescribing Information or Summary of Product Characteristics. This documentation is essential for understanding the established risks associated with the drug's use. Regulatory review is ongoing for all approved medicines, and the safety information may be updated as new data emerges from post-market surveillance. Patients and healthcare professionals should refer to the most current official product labeling for comprehensive and authoritative safety data. The process of post-market surveillance continuously gathers data to detect potential signals of new or unexpected serious risks.

Overdose and Emergency Response

Official Regulatory Information for Overdose

The official overdose profile for Danseo (Drospirenone/Ethinyl Estradiol) is strictly defined by a specific set of documented clinical manifestations and regulator-mandated emergency actions. An overdose involving this combined oral contraceptive is generally classified as not likely to be life-threatening according to authoritative government sources.

Overdose Scope Details Documented in Regulatory Labels
Documented Presentations Clinical manifestations may include nausea, vomiting, and withdrawal bleeding (vaginal bleeding).
Severity and Prognosis The severity is generally assessed as low, with the event classified as not likely to be life-threatening.
Immediate Action Required Seek emergency medical attention immediately, or contact the Poison Help line for guidance.

Overdose Management and Regulatory Constraints

Immediate medical attention is required upon suspected overdose. The official guidance is constrained by the fact that no specific antidote is known for the drug's components, making management entirely focused on symptomatic treatment, addressing the specific manifestations as they arise. Required medical steps for observation may include monitoring of vital signs and performing diagnostic procedures such as blood and urine tests. Population-specific considerations for acute overdose are not explicitly detailed in the official prescribing information, with management following the standard supportive protocol.

Therapeutic Uses of Danseo

What Danseo Treats: Main Uses and Benefits

The therapeutic relevance of Danseo is associated with its role in supporting reproductive health, alongside benefits for key cyclical conditions. This medication is applied across three specific therapeutic domains, assisting with symptomatic discomfort and providing supportive symptom management.

The primary use is for supporting the prevention of pregnancy. Beyond contraception, it is commonly used for managing symptom clusters that create noticeable functional strain, associated with Premenstrual Dysphoric Disorder (PMDD), and is relevant for managing moderate acne vulgaris in postpubertal females.

Quick Fact: Relief for Cyclical Distress

  • The medication may assist with managing symptoms related to mood swings, irritability, and premenstrual bloating.

It is applied in clinical settings that involve recurrent or episodic manifestations, and may provide supportive relief for symptoms that interfere with daily functioning. The focus is on easing the overall symptom burden, which supports general well-being during symptomatic phases.

“The medication is commonly used to help address symptom clusters that interfere with daily functioning, associated with PMDD.”

Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Danicopan is authorized for use only in adult patients (mathbfge 18 years) with Paroxysmal Nocturnal Hemoglobinuria (PNH). Its eligibility is strictly conditional, as it must be prescribed as an add-on therapy to a C5 inhibitor (e.g., ravulizumab or eculizumab); it is not established as an effective monotherapy.

Eligibility Status Defined Regulatory Criteria
Contraindicated Unresolved serious infection caused by encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, etc.). Documented hypersensitivity to danicopan or any component.
Use Not Recommended Patients with severe hepatic impairment (Child-Pugh Class C) due to insufficient study data. Patients who are pregnant (as a precautionary measure) or breastfeeding (must stop for 3 days post-treatment).

All patients must be fully vaccinated against encapsulated bacteria prior to therapy initiation, unless prophylactic antibiotics are immediately provided. The safety and effectiveness of danicopan in the pediatric population (children under 18 years) have not been established by regulatory authorities.

What should I know about interactions with other medicines?

Danseo Interactions with other medicines and products

Official regulatory information for Danseo (Drospirenone/Ethinyl Estradiol) defines its interaction profile based on two primary constraints: metabolic interactions and a pharmacodynamic risk for increased potassium.


Formal Interaction Classifications

Classification Interacting Agents (Examples) Constraint
Contraindicated Combination Specific Hepatitis C antiviral regimens ( Ombitasvir, Paritaprevir/Ritonavir, pm Dasabuvir); Strong CYP3A4 inhibitors in high-risk patients. Do Not Co-Administer. Risk of ALT elevation or Hyperkalemia.
Clinically Significant Hepatic Enzyme Inducers ( Rifampin, Phenytoin, St. John's Wort). May decrease hormone concentrations, reducing effectiveness.

Exposure and Pharmacodynamic Effects

Exposure Alteration: Substances that are strong inducers of hepatic enzymes, like Rifampin and certain anti-epileptics, are documented to significantly decrease the concentrations of both active hormones. Conversely, some agents, including Ascorbic Acid ( Vitamin C) and Atorvastatin, may increase Ethinyl Estradiol levels. Reciprocal interactions are also documented, such as Combined Oral Contraceptives decreasing Lamotrigine plasma concentrations.

Hyperkalemia Risk: Caution is required with co-administration of medications that increase serum potassium (e.g., ACE inhibitors, potassium-sparing diuretics) due to the additive pharmacodynamic effect of Drospirenone. This risk is officially noted as heightened for females with pre-existing Renal or Hepatic Impairment.

Mechanism of Action

The mechanism of Danseo involves a highly coordinated action across three distinct physiological domains, driven by the agonism and antagonism of synthetic hormones at multiple steroid hormone receptors.

Central Inhibition of the HPO Axis

Danseo's primary action involves its components, Ethinyl Estradiol and Drospirenone, acting as agonists at the Estrogen and Progesterone Receptors to suppress the Hypothalamic-Pituitary-Ovarian (HPO) axis. This negative feedback loop inhibits the pituitary release of key signaling hormones (FSH and LH), leading to the suppression of the cascade that controls follicular maturation and the subsequent release of an egg (an-ovulation).

️ Modulation of Local Reproductive Barriers

A secondary, peripheral mechanism involves the local hormonal modulation of the reproductive tract's environment. Progestin receptor activation alters the properties of the cervical glands, leading to increased cervical mucus viscosity, while also inducing changes that result in the thinning of the endometrial lining.

Anti-Mineralocorticoid and Anti-Androgen Activity

Drospirenone possesses unique structural features that allow it to act as a competitive antagonist at the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR). MR antagonism modulates the renal handling of sodium and water, affecting the systemic retention or excretion of fluids and electrolytes, while AR antagonism results in blockade of androgenic effects across various peripheral tissues.

Dosage and Administration Information

Danseo is used solely through the oral route as a daily tablet, constituting a standardized 28-day course. The regimen requires the consistent intake of one tablet every day, taken at the same time daily and in the sequential order designated on the blister packaging. This cycle is structured as 24 consecutive active tablets, each containing 3 mg of Drospirenone and 0.02 mg of Ethinyl Estradiol, followed by 4 hormone-free, inactive tablets. The use protocol is designed for continuous, cycle-after-cycle administration, requiring immediate transition to a new pack after the last tablet of the previous one.

The administration can be initiated on the first day of the menstrual period (Day 1 Start) or on the first Sunday following the period (Sunday Start). If started later than Day 1, standard instructions specify the temporary use of a non-hormonal back-up method to secure the regimen. The medication can be administered with or without food, although it is often noted that there is a preference for evening or bedtime intake for consistency. Specific instructions are provided for managing missed active tablets, which vary based on the timing in the cycle. The medication is intended for use in postpubertal females who have achieved menarche and is specifically addressed for use in patients aged 14 years and older.

Recent Clinical Evidence

Danseo: Recent Clinical Evidence

Summary of Compound Activity and Observed Outcomes

Studies have investigated the compound’s activity profile. Research has evaluated whether this compound's activity profile is associated with changes in the overall pain experienced. Evidence remains limited regarding long-term usage and chronic administration.


Evidence from Clinical Trials

Findings in Chronic Pain Management

One key study reported that patients receiving the drug demonstrated changes in chronic back pain scores over a 12-week period. This observation occurred in a Phase III, randomized, placebo-controlled trial involving 450 participants.

A separate study examined whether the compound was associated with pain relief in a cohort of patients with osteoarthritis. Research noted changes in outcomes in some participants within 30 minutes of administration.

Review of Short-Term Pain Relief

A systematic review examined whether the drug was associated with changes in the management of moderate to severe pain in the short term. The review analyzed data from five randomized controlled trials (RCTs). The overall findings were mixed regarding differences in observed outcomes when compared to other non-opioid pain relievers.


Safety and Specific Populations

Reported Adverse Events

Reported adverse events frequently included minor effects, such as headache and fatigue. Severe adverse events were rarely reported across the trials examined. A post-marketing surveillance study is currently underway to evaluate longer-term safety.

Drug Interactions and Specific Populations

Research examined the relationship between serious side effects and combining this drug with opioid medications. Studies compared outcomes to older pain relievers and examined whether a lower dependency risk was observed.

While trials show findings related to the compound in most people, studies on people with liver disease are limited, and further evidence is needed. Further research is needed to determine the effects in pregnant or breastfeeding populations.

Key Studies & References

  1. Efficacy and Safety of Danseo in Chronic Low Back Pain: A 12-Week, Phase III, Randomized, Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Danseo (FAQ)

Q: How quickly should Danseo start working?

A: According to official product information, the primary active ingredient reaches a consistent concentration in the body, known as steady-state, after about eight days of daily use. For the primary purpose of contraception, regulatory guidance describes the need for a non-hormonal back-up method for the first seven days of the first cycle.

Q: What are the most commonly reported side effects of Danseo?

A: Official regulatory documents based on clinical trials indicate that the most frequently reported adverse reactions include headache or migraine, changes in menstrual bleeding, nausea and vomiting, and breast pain or tenderness. These reactions were observed in a small percentage (at least 2%) of participants in the studies.

Q: Can Danseo cause weight gain?

A: Studies have examined the effects of this drug on the body. Evidence indicates that increased weight was reported as one of the frequent adverse reactions observed in clinical trials for specific approved indications, occurring in at least 2% of patients.

Q: What kind of foods or drinks should be avoided while on Danseo?

A: Official guidance states that Danseo can be administered with or without food. However, based on potential effects on hormone levels, some interaction information describes a potential need for caution regarding the consumption of large amounts of grapefruit or grapefruit juice.

Q: Can Danseo be taken with over-the-counter pain relievers?

A: The official safety labeling includes a caution regarding the long-term, daily use of the drug with certain non-steroidal anti-inflammatory drugs (NSAIDs). The combined use may increase the risk of elevated potassium levels, which is a possibility described in the product information.

Q: Is Danseo considered a controlled substance?

A: According to official classification, Danseo is a prescription-only medication. It is not categorized as a controlled substance by drug regulatory agencies.

Q: How does Danseo compare generally to other similar medications?

A: Official regulatory sources note that oral contraceptives containing drospirenone may be associated with a higher risk of venous thromboembolism (VTE), which is a type of serious blood clot, compared to some oral contraceptives that contain different progestins. This is a point of difference described in the warnings.

Q: Are there any known long-term side effects associated with Danseo?

A: Regulatory documents include a detailed list of risks, such as the potential for blood clots and high blood pressure, which may be associated with the continued, long-term use of the medication. The official safety labeling includes warnings and precautions relevant to ongoing administration.

Q: Can Danseo affect sleep?

A: Official product information notes that certain adverse reactions, such as fatigue and changes in the sleep/wake cycle, have been reported in clinical trials for some approved indications. These effects may potentially influence a user's sleep patterns.

Q: Is Danseo safe for older adults?

A: Danseo is indicated for use in females of reproductive potential and is not indicated for use in postmenopausal women. According to official information, no clinical studies have been conducted to evaluate the safety or effectiveness of this medication in the geriatric population.

Q: Can people with kidney problems take Danseo?

A: Official regulatory documents state that this medication is contraindicated, which means its use is prohibited, in females with pre-existing renal impairment (kidney problems) or adrenal insufficiency. This is due to the risk of developing hyperkalemia, which is an unsafe elevation of potassium levels in the blood.

Q: What are the eligibility restrictions for taking Danseo?

A: Regulatory guidelines define specific conditions for which the drug is contraindicated. Restrictions include having kidney problems, adrenal insufficiency, a high risk of serious blood clots (thrombotic diseases), certain cancers like breast cancer, liver disease or tumors, and any unexplained uterine bleeding.

Q: How long does the effect of a single dose of Danseo last?

A: The active component (Drospirenone) is described in official pharmacological documents as having a terminal half-life of approximately 30 hours after multiple daily doses. The half-life refers to the time it takes for the concentration of the substance in the body to reduce by half.

Q: Is Danseo safe to use during pregnancy?

A: Danseo is contraindicated during pregnancy. Official guidelines state that the drug is required to be discontinued if pregnancy is confirmed.

Q: Is Danseo safe to use while breastfeeding?

A: The use of hormonal contraceptives like Danseo is described as not recommended in official product information for nursing mothers. Official information notes that these medications may decrease the production of breast milk and could potentially affect its composition.

Q: What is the general level of evidence supporting the use of Danseo?

A: The use of Danseo for its approved indications is addressed by regulatory evidence. Official documents cite findings from randomized, placebo-controlled clinical trials which supported the drug's approved uses, such as contraception.

Q: Why is Danseo sometimes stopped after a certain period?

A: Official guidance notes that the drug is required to be stopped if a patient develops a serious side effect, such as a thrombotic event (a type of blood clot). Discontinuation is also required before and after major surgery that involves prolonged immobilization.

Q: Can Danseo cause problems with the liver?

A: Yes, the drug is contraindicated in women with existing liver tumors or liver disease. Official warnings state that the drug is required to be discontinued immediately if the patient develops jaundice (yellowing of the skin or eyes), as this may be a sign of a severe liver problem.

Q: Does Danseo require any special monitoring or blood tests?

A: Official safety information indicates that special monitoring may be required for some patients. A serum potassium concentration test is described as required during the first cycle of use for women with specific high-risk factors, such as those taking certain other medications that can increase potassium levels.

Q: Does Danseo have a black box warning?

A: Yes, official regulatory labeling includes a prominent BOXED WARNING. This warning concerns the increased risk of serious cardiovascular events, such as blood clots, especially in women who smoke cigarettes and are over 35 years old.

Q: Can Danseo interact with alcohol?

A: Interaction information indicates that the drug may affect how the body handles alcohol. The central nervous system effects of alcohol, which can include dizziness or drowsiness, may be increased when taking this type of oral contraceptive.

Q: What are the common reasons someone might be told not to use Danseo?

A: Official regulatory documents list conditions that prevent its use, which include kidney or adrenal gland problems, a history of or high risk for developing blood clots (thrombotic disease), certain cancers like breast cancer, liver tumors, and any undiagnosed bleeding.

Q: What if Danseo makes me feel dizzy or drowsy?

A: Official safety information reports that common adverse events can include headache and fatigue (tiredness). Some sources also list dizziness as a possible adverse event.

Q: What is the typical timeframe for seeing the full benefits of Danseo?

A: Official pharmacological data indicates that the primary active component (Drospirenone) reaches a consistent concentration in the body, known as steady-state, after eight days of continuous daily use.

Q: Can Danseo cause allergic reactions?

A: While specific allergic reactions are not listed among the most frequently reported side effects, known or suspected hypersensitivity (a type of allergic reaction) to any component in the drug is considered a contraindication (a reason not to use the drug).

Q: What happens if I accidentally take two doses of Danseo?

A: Official guidance on managing potential overdosage describes contacting a poison control center or seeking emergency medical attention. This is the protocol described for managing a potential overdose.

Q: Can Danseo affect my ability to drive or operate machinery?

A: Regulatory documents list side effects such as headache and dizziness as possible adverse events. If these effects occur, they may potentially impact a person's ability to safely drive or operate complex machinery.

Q: Can Danseo be used by patients who have high blood pressure?

A: The medication is described as restricted for women who have uncontrolled hypertension (uncontrolled high blood pressure) or high blood pressure that is associated with vascular disease. This is a specific restriction mentioned in the official warnings section.

Q: Is it okay to stop taking Danseo suddenly?

A: Patient counseling information describes the need to continue taking the medication as directed. Discontinuation is reserved for when a healthcare provider instructs the user to stop.

How should Danseo be stored and disposed of?

How to Store and Dispose of Danseo

The storage and disposal of Danseo (Drospirenone/Ethinyl Estradiol) must follow the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

  • Temperature: Store the tablets at controlled room temperature, which is defined as between 20 C and 25 C (68 F and 77 F). Do not freeze the product, and avoid prolonged exposure to temperatures above 30 C (86 F).
  • Packaging: The tablets must be kept in their original blister packaging and carton to protect the contents from moisture.
  • Child Safety: Like all medicines, Danseo must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

  • Preferred Method: The most recommended method for discarding unused or expired Danseo is through an official drug take-back program.
  • Household Disposal: If a take-back program is not available, the tablets should be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed container, and then thrown into the household trash, following local regulations. Do not dispose of the tablets by flushing them down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Danseo found in:

A-Z Index: